Research shows that the administration of LXA4 methyl ester (LXA4ME) reduces the amount of pro-inflammatory cytokines, tumor necrosis factor-α (TNF-α), interleukin-1β (Il-1β), and increases anti-inflammatory cytokines: IL-10 and transforming growth factor-β1 (TGF-β1) after cerebral ischemia [5,82,83]. This evidence concerns the gene TNF and brain ischemia.